Bevacizumab (Avastin®, Genentech, San Francisco, CA, USA) is an intravenously administered monoclonal antibody targeting vascular endothelial growth factor (VEGF) that alters tumour vasculature (Yoshida et al. 2015). The gene discussed is VEGFA; the disease is neoplasm.